Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA CEL-SCI Corporation (NYSE:CVM) today announced it is launching its global Confirmatory Registration Study of
Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine® in the treatment of head and neck cancer in Saudi Arabia with option to extend to Gulf Cooperation Council countries CEL-SCI Corporation (NYSE:CVM) today announced the successful conclusion of a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 on June 22nd in San Diego, marking a significant step forward in U.S.–Saudi cooperation in healthcare innovation and oncology. This press release features multimedia. View t
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $2.5 million.The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.ThinkEquity acted as the sole placement agent for the offering.The securities were offered and sold pursuant to a
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
DEF 14A - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
424B5 - CEL SCI CORP (0000725363) (Filer)
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)